Navigation Links
Arcturus Therapeutics Announces Collaboration with Takeda Pharmaceuticals to Develop RNA-based Therapeutics for the Treatment of Nonalcoholic Steatohepatitis (NASH)
Date:12/6/2016

SAN DIEGO, Dec. 6, 2016 /PRNewswire/ -- Arcturus Therapeutics, Inc. ("Arcturus" or the "Company"), a leading RNA medicines company, announced today that it entered into collaboration with Takeda Pharmaceutical Company Limited, to develop RNA-based therapeutics for the treatment of NASH and other gastrointestinal (GI) related disorders, utilizing Arcturus' wholly-owned therapeutic delivery platform LUNAR™ and UNA Oligomer chemistry. The financial terms were not disclosed.

"Given Takeda's long-standing commitment to and expertise in GI disorders, we are confident we have found an ideal partner to accelerate and maximize the potential of our LUNAR and UNA technology platforms toward the development of novel RNA therapeutics for the treatment of NASH," said Dr. Pad Chivukula, CSO & COO of Arcturus Therapeutics, Inc. "This agreement underscores Arcturus' ability to rapidly discover, design and optimize RNA medicines in areas of unmet need." 

About Arcturus Therapeutics, Inc.   

Founded in 2013 and based in San Diego, Arcturus Therapeutics, Inc. is an RNA medicines company with enabling technologies — UNA Oligomer chemistry and LUNAR™ nanoparticle delivery. Arcturus' versatile RNA therapeutics platform can be applied toward all types of RNA medicines including small interfering RNA, messenger RNA, antisense RNA, microRNA and gene editing therapeutics. The company owns LUNAR™ nanoparticle delivery and unlocked nucleomonomer agent (UNA) technology including UNA Oligomers™, which are covered by its patent portfolio (77 patents and patent applications, issued in the U.S., Europe, Japan and other countries). Arcturus' proprietary UNA technology can be used to target any gene in the human genome, as well as viral genes, and other species for therapeutic purposes. The Company's commitment to the development of novel RNA therapeutics has led to collaborations and license agreements with Janssen Pharmaceuticals, Inc., part of the Janssen Pharmaceutical Companies of Johnson & Johnson, and Ultragenyx Pharmaceutical, Inc. For more information, visit www.ArcturusRx.com.

Logo - http://photos.prnewswire.com/prnh/20130531/MM24393LOGO

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/arcturus-therapeutics-announces-collaboration-with-takeda-pharmaceuticals-to-develop-rna-based-therapeutics-for-the-treatment-of-nonalcoholic-steatohepatitis-nash-300373830.html


'/>"/>
SOURCE Arcturus Therapeutics
Copyright©2016 PR Newswire.
All rights reserved


Related medicine technology :

1. Arcturus Therapeutics Receives Intent to Grant Notice from the European Patent Office for their Unlocked Nucleomonomer Agent (UNA) Technology
2. Arcturus Therapeutics Announces the Appointment of Drew Weissman M.D., Ph.D. to the Scientific Advisory Board
3. Arcturus Therapeutics Announces Strategic Collaboration with Johnson & Johnson Innovation to Discover and Develop RNA Medicines for Defined Indications
4. Arcturus Therapeutics to Present at the Genetic Rx Boston Biotech Conference
5. Arcturus Therapeutics to Present at the 26th Annual Piper Jaffray Healthcare Conference
6. Arcturus Therapeutics, Inc. Announces an RNAi Therapeutic Targeting Transthyretin-mediated Amyloidosis as its Flagship Program
7. Arcturus Therapeutics Acquires Cutting-Edge UNA Patent Estate from Marina Biotech
8. Viking Therapeutics Receives Orphan Drug Designation for VK0214 from the U.S. Food and Drug Administration for the Treatment of X-Linked Adrenoleukodystrophy
9. Mission Therapeutics Appoints Colin Goddard as Chairman
10. Research Reports Initiation on Healthcare Stocks -- NuVasive, Smith & Nephew, Nxstage Medical, and Cesca Therapeutics
11. Research Reports Coverage on Biotech Stocks -- Celldex Therapeutics, Amicus Therapeutics, Navidea Biopharma, and Concordia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/2/2018)... (PRWEB) , ... August 02, 2018 , ... UMD Professor ... to $7.7 million over 5 years from the National Institute of Allergy and Infectious ... research program to understand the immune responses of ticks that contribute to the spread ...
(Date:8/2/2018)... ... , ... Clay and Associates DDS, PLC is excited to welcome Dr. Tyler ... John Clay and Dr. Shaun O’Neill as an associate dentist to the practice. , ... patients' dental hygiene, encapsulates the core values of the professional dental team at Clay ...
(Date:8/2/2018)... , ... August 02, 2018 , ... ... humanitarian efforts, is an inspiring, international leader of sustainable advocacy. Sharon Kleyne, host ... Pharma®, The Power of Water® & Your Health sponsored by Nature’s Tears® EyeMist® ...
Breaking Medicine Technology:
(Date:8/14/2018)... ... August 14, 2018 , ... Health & hygiene ranked eighth ... is the largest study of brands based on emotions. In the U.S., Olay again ... 10 for the health & hygiene industry were: Listerine, Nivea, Gillette, Colgate, Head & ...
(Date:8/11/2018)... ... August 10, 2018 , ... TopConsumerReviews.com recently awarded a five-star ... gout? This painful, persistent condition originates in the liver and is characterized by ... acid. Other contributing factors may be medication side effects, overweight, and unhealthy diet. ...
(Date:8/9/2018)... ... August 09, 2018 , ... Lyme disease is one of the ... to an estimated 329,000 – a 25-fold increase since surveillance began in 1982. According ... be found all 50 states and the District of Columbia. Yet, Lyme and other ...
(Date:8/7/2018)... ... August 07, 2018 , ... Josh Sprague, Founder and CEO of ... preview for the upcoming Leadville 100 MTB. , Accompanied by colleague Marvin Sandoval ... he has called “one of the most iconic mountain bike race courses in the ...
(Date:8/3/2018)... ... , ... On August 2, 2018 the JPML ordered that the Zostavax MDL ... LLC has been litigating Zostavax injuries since 2011. , ... for the thousands of people injured by Zostavax, a vaccine given to adults to ...
Breaking Medicine News(10 mins):